Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

Executive Summary

Things couldn't have gone any worse for Bristol-Myers Squibb's Opdivo in the CheckMate 026 lung cancer data presented at ESMO. Without even a trend towards efficacy in patients with high levels of PD-L1 expression, imminent erosion of market share by Merck's Keytruda seems inevitable.


Related Content

TMB Biomarker Is A Winding Path Rather Than Straight Road
Bristol Debuts Opdivo/Yervoy Data In New First-Line Lung Cancer Bid
PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride
Bristol's Opdivo/Yervoy Combo Beats Sutent On Survival In Renal Cancer
Another Opdivo Disappointment For BMS, This Time In Kidney Cancer
AstraZeneca Hopes Imfinzi Breakthrough Get Can Burn Off MYSTIC Failure
Soriot Stands By His Post-Pfizer Sales Pledge For AstraZeneca
ESMO Preview: Opdivo Under Pressure
Does CheckMate 026 Take Bristol Out Of The End Game?
What's Next For Bristol's Opdivo/Yervoy Combination


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts